Oppenheimer Holdings, Inc. began coverage on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a report issued on Tuesday, July 18th. The brokerage issued a market perform rating on the stock. Oppenheimer Holdings also issued estimates for Intellia Therapeutics’ Q2 2017 earnings at ($0.39) EPS, Q3 2017 earnings at ($0.44) EPS, Q4 2017 earnings at ($0.47) EPS, FY2017 earnings at ($1.66) EPS, Q1 2018 earnings at ($0.51) EPS, Q2 2018 earnings at ($0.55) EPS, Q3 2018 earnings at ($0.55) EPS, Q4 2018 earnings at ($0.58) EPS, FY2018 earnings at ($2.19) EPS, FY2019 earnings at ($3.50) EPS, FY2020 earnings at ($4.77) EPS and FY2021 earnings at ($3.74) EPS.
A number of other brokerages have also recently commented on NTLA. Cann restated a market perform rating on shares of Intellia Therapeutics in a research note on Monday, July 17th. TheStreet upgraded Intellia Therapeutics from a d+ rating to a c- rating in a research note on Thursday, July 6th. Wedbush reiterated an outperform rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, May 15th. Jefferies Group LLC reissued a buy rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a report on Thursday, June 22nd. Finally, Credit Suisse Group set a $24.00 price objective on Intellia Therapeutics and gave the company a buy rating in a report on Wednesday, May 3rd. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $24.83.
Shares of Intellia Therapeutics (NASDAQ:NTLA) traded up 4.57% during trading on Tuesday, hitting $16.93. The stock had a trading volume of 200,577 shares. The company’s market cap is $611.38 million. The stock’s 50 day moving average is $16.45 and its 200-day moving average is $14.30. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $24.90.
Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.03. The company had revenue of $5.90 million for the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The business’s revenue was up 40.5% compared to the same quarter last year. Analysts forecast that Intellia Therapeutics will post ($1.74) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/14/intellia-therapeutics-inc-nasdaqntla-coverage-initiated-by-analysts-at-oppenheimer-holdings-inc-updated-updated-updated.html.
In related news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 12.80% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Airain ltd bought a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $381,000. M&T Bank Corp bought a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $162,000. Paulson & CO. Inc. bought a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $1,107,000. Norges Bank bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $886,000. Finally, UBS Group AG increased its stake in shares of Intellia Therapeutics by 432.0% in the first quarter. UBS Group AG now owns 60,935 shares of the company’s stock worth $859,000 after buying an additional 49,480 shares during the period. Institutional investors own 46.88% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.